阿森迪斯制药

最新新闻

• 评级变动
  BMO Capital Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $319
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 评级变动
  A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $273 to $344
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Raymond James Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $287
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $344
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $327
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 评级变动
  A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $326 to $360
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• 评级变动
  H.C. Wainwright Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $345
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $275 to $360
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• Morgan Stanley Initiates Ascendis Pharma A/S(ASND.US) With Buy Rating, Announces Target Price $273
  \u5e02\u573a\u8d44\u8baf · 2026/10/4
• 评级变动
  A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $304 to $344
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $290
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $329
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $275
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273
  \u5e02\u573a\u8d44\u8baf · 2026/9/28

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。